The treatment of conditions that may cause secondary parkinsonism may decrease the risk of its development. Medication use should only be under the supervision of the health care provider and people with conditions that require long-term use of antipsychotics, like schizophrenia, should be carefully monitored to avoid development of irreversible secondary parkinsonism. Newer antipsychotic medications are less likely to cause secondary parkinsonism.
U.S. Food and Drug Administration. FDA Approves Neupro Patch for Treatment of Early Parkinson's Disease . Rockville, MD: National Press Office; May 9, 2007. Release P07-84.
Goetz, CG. Textbook of Clinical Neurology . 2nd ed. St. Louis, Mo: WB Saunders; 2003: 713-720.
Noble J. Textbook of Primary Care Medicine . 3rd ed. St. Louis, Mo: Mosby; 2001:1612-1618.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |